Industry: Mitochondria-targeted therapies
PartiKula is developing cancer therapies targeting mitochondria, an organelle that produces energy in the cell. Mitochondrial dysfunction is linked to many diseases, including cancer, heart disease and neurodegenerative conditions.
PartiKula’s technology is based on a key platform that delivers therapeutics directly to the mitochondria, an important accomplishment. The company is using this technology to target mitochondria with compounds that inhibit cancer metabolism at the source.
This therapy may offer a new avenue for providing effective, safe treatment for the 1.6 million new cases of cancer each year. Currently, there are no approved mitochondrial-targeted therapeutics for this disease.
Company website: PartiKula